Latest Solifenacin Stories
DEERFIELD, Ill., May 17, 2011 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas Pharma US"), U.S. subsidiary of Astellas Pharma Inc.
TOKYO, March 22, 2011 /PRNewswire-FirstCall/ -- Astellas Pharma Inc.(TSE:4503,"Astellas") ( http://www.astellas.com/en/corporate/) today announced the results of two pivotal phase III clinical trials for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB), show mirabegron significantly improves key OAB symptoms - urinary incontinence and frequency of micturition[1,2]. These data were presented for the first time this week at the...
Canadian study (VECTOR) presented at the 2009 American Urological Association Annual Meeting CHICAGO, April 30 /PRNewswire/ - Patients with overactive bladder (OAB) treated with solifenacin reported significantly lower incidence and severity of dry mouth, an often intolerable anti-cholinergic side effect, than those treated with oxybutynin immediate-release (IR).
Pfizer Inc said today that the U.S. Food and Drug Administration (FDA) approved TOVIAZ(TM) (fesoterodine fumarate) extended release tablets for the treatment of overactive bladder (OAB) symptoms.
Q: You mentioned several types of medications that increase the risk of hyperthermia during hot weather. Would you provide a detailed list? A: Hot weather can cause the body to overheat, called hyperthermia. The evaporation of sweat is the body's primary way of cooling off.